Drug Profile
LHF 535
Alternative Names: LHF-535; LHF-535-SDDLatest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator SIGA Technologies
- Developer Kineta Viral Hemorrhagic Fever
- Class Antivirals; Small molecules
- Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lassa fever
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Lassa-fever in USA (PO)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Lassa-fever(In volunteers) in Australia (PO)
- 25 Mar 2021 Pharmacokinetics and adverse events data from a phase Ib trial in in Lassa fever (In volunteers) released by Kineta